(Q88485831)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

meta-analysis

0 references

title

Memantine for dementia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Emmert Roberts

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

author name string

Rupert McShane

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Neda Minakaran

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Lon Schneider

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Lucy E Farrimond

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Nicola Maayan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Jennifer Ware

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Jean Debarros

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

language of work or name

English

0 references

publication date

20 March 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

30 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

page(s)

CD003154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

12 December 2020

Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study

1 reference

12 December 2020

Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial

1 reference

12 December 2020

A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients).

1 reference

12 December 2020

A description of agitation in a nursing home

1 reference

12 December 2020

[The usefulness of BOP and SIVIS (ADL and behavior rating scales) for the estimation of workload in a psychogeriatric nursing home. Results of a time-standard study]

1 reference

12 December 2020

Treatment of Impaired Cerebral Function in Psychogeriatric Patients with Memantine - Results of a Phase II Double-Blind Study

1 reference

12 December 2020

Memantine in the treatment of senile dementia of the Alzheimer type.

1 reference

12 December 2020

A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment--Geriatric (SCAG).

1 reference

12 December 2020

NOSIE--30: history and current status of its use in pharmacopsychiatric research

1 reference

12 December 2020

A new rating scale for Alzheimer's disease.

1 reference

12 December 2020

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

12 December 2020

A new rating scale for dementia syndromes

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

Factor structure and scoring of the SKT test battery.

1 reference

12 December 2020

NMDA receptors: from genes to channels

1 reference

12 December 2020

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

1 reference

12 December 2020

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

12 December 2020

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

1 reference

12 December 2020

Slowing the progression of Alzheimer disease: ethical issues.

1 reference

12 December 2020

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

1 reference

12 December 2020

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

1 reference

12 December 2020

Executive control function: a rational basis for the diagnosis of vascular dementia

1 reference

12 December 2020

Overlap between pathology of Alzheimer disease and vascular dementia

1 reference

12 December 2020

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

12 December 2020

Weighing the benefits of new Alzheimer's treatments.

1 reference

12 December 2020

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

1 reference

12 December 2020

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

1 reference

12 December 2020

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

1 reference

12 December 2020

Memantine in moderate-to-severe Alzheimer's disease

1 reference

12 December 2020

A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome

1 reference

12 December 2020

1 reference

12 December 2020

FDA approves memantine drug for treating AD

1 reference

12 December 2020

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

12 December 2020

Memantine for patients with Alzheimer disease

1 reference

12 December 2020

Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

1 reference

12 December 2020

[Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial].

1 reference

12 December 2020

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

12 December 2020

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

1 reference

12 December 2020

A pilot study of the clinical efficacy and safety of memantine for Huntington's disease

1 reference

12 December 2020

A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).

1 reference

12 December 2020

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.

1 reference

12 December 2020

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

1 reference

12 December 2020

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.

1 reference

12 December 2020

Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.

1 reference

12 December 2020

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.

1 reference

12 December 2020

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

1 reference

12 December 2020

Memantine (Ebixa) in clinical practice - results of an observational study.

1 reference

12 December 2020

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

1 reference

12 December 2020

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials

1 reference

12 December 2020

Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease.

1 reference

12 December 2020

Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.

1 reference

12 December 2020

Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study.

1 reference

12 December 2020

A 6-month, open-label study of memantine in patients with frontotemporal dementia.

1 reference

12 December 2020

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease

1 reference

12 December 2020

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies

1 reference

12 December 2020

Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.

1 reference

12 December 2020

Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study

1 reference

12 December 2020

Efficacy and safety of memantine in dementia with Lewy bodies

1 reference

12 December 2020

Long-term course and effectiveness of combination therapy in Alzheimer disease

1 reference

12 December 2020

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine

1 reference

12 December 2020

Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia

1 reference

12 December 2020

Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia

1 reference

12 December 2020

Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation

1 reference

12 December 2020

Memantine induces reversible neurologic impairment in patients with MS.

1 reference

12 December 2020

Efficacy of memantine in Parkinson's disease with dementia

1 reference

12 December 2020

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies

1 reference

12 December 2020

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

1 reference

12 December 2020

Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia

1 reference

12 December 2020

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

1 reference

12 December 2020

Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention

1 reference

12 December 2020

General risk factors for dementia: a systematic evidence review

1 reference

12 December 2020

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

1 reference

12 December 2020

An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration

1 reference

12 December 2020

Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy

1 reference

12 December 2020

Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease

1 reference

12 December 2020

Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia

1 reference

12 December 2020

Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil

1 reference

12 December 2020

Effect of memantine treatment on regional cortical metabolism in Alzheimer's disease

1 reference

12 December 2020

Memantine for AIDS dementia complex: open-label report of ACTG 301.

1 reference

12 December 2020

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

1 reference

12 December 2020

Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members

1 reference

12 December 2020

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Pilot trial of memantine in primary progressive aphasia.

1 reference

12 December 2020

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

1 reference

12 December 2020

The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia

1 reference

12 December 2020

Memantine benefits functional abilities in moderate to severe Alzheimer's disease

1 reference

12 December 2020

Memantine prevents hypoglycemia-induced decrements of the cerebral energy status in healthy subjects

1 reference

12 December 2020

Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ß production.

1 reference

12 December 2020

Memantine in behavioral variant frontotemporal dementia: negative results.

1 reference

12 December 2020

Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial.

1 reference

12 December 2020

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative

1 reference

12 December 2020

Effect of memantine on resting state default mode network activity in Alzheimer's disease

1 reference

12 December 2020

[Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]

1 reference

12 December 2020

Validity and responsiveness to change of clinically derived MDS scales in Alzheimer disease outcomes research.

1 reference

12 December 2020

Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

1 reference

12 December 2020

GRADE guidelines 6. Rating the quality of evidence—imprecision

1 reference

12 December 2020

MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia

1 reference

12 December 2020

Does Memantine Improve the Gait of Individuals with Alzheimer's Disease?

1 reference

12 December 2020

Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial.

1 reference

12 December 2020

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

1 reference

12 December 2020

Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.

1 reference

12 December 2020

Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial

1 reference

12 December 2020

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.

1 reference

12 December 2020

A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.

1 reference

12 December 2020

[Efficacy, safety and tolerability of a single dose of akatinol memantine in comparison to two-doses in patients with moderately expressed and moderately severe dementia in Alzheimer's disease]

1 reference

12 December 2020

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

1 reference

12 December 2020

ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease.

1 reference

12 December 2020

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.

1 reference

12 December 2020

Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study

1 reference

12 December 2020

Comparative cardiovascular safety of dementia medications: a cross-national study

1 reference

12 December 2020

Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias

1 reference

12 December 2020

Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

1 reference

12 December 2020

A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease

1 reference

12 December 2020

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.

1 reference

12 December 2020

Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data

1 reference

12 December 2020

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

1 reference

12 December 2020

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.

1 reference

12 December 2020

Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial

1 reference

12 December 2020

Vitamin E, memantine, and Alzheimer disease.

1 reference

12 December 2020

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial

1 reference

12 December 2020

The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.

1 reference

12 December 2020

Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia.

1 reference

12 December 2020

Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan

1 reference

12 December 2020

Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies

1 reference

12 December 2020

Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis

1 reference

12 December 2020

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study

1 reference

12 December 2020

Efficacy of memantine hydrochloride once-daily in Alzheimer's disease

1 reference

12 December 2020

Systematic review of recent dementia practice guidelines

1 reference

12 December 2020

A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).

1 reference

12 December 2020

Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis

1 reference

12 December 2020

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

1 reference

12 December 2020

Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis

1 reference

12 December 2020

Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials

1 reference

12 December 2020

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis

1 reference

12 December 2020

Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.

1 reference

12 December 2020

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

1 reference

12 December 2020

Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).

1 reference

12 December 2020

Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study.

1 reference

12 December 2020

Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology

1 reference

12 December 2020

Risk factors for dementia in the ninth decade of life and beyond: a study of the Lothian birth cohort 1921

1 reference

12 December 2020

Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis

1 reference

12 December 2020

Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.

1 reference

12 December 2020

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease.

1 reference

12 December 2020

10.1002/14651858.CD003154.PUB6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30891742%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference